期刊
BLOOD
卷 127, 期 20, 页码 2375-2390出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2016-01-643569
关键词
-
类别
资金
- Italian Association for Cancer Research (AIRC, Milan) [10007]
- National Institutes of Health (NIH)/National Cancer Institute (NCI) Cancer Center [P30 CA008748]
- American Society of Hematology
- Josep Carreras Foundation
- Fondazione Italiana Linfomi (FIL)
- Leukemia Clinical Research Foundation
- University of Chicago Comprehensive Cancer Center
- Beckman Coulter Corporation
- Celgene Corporation
- Dako
- Genentech Corporation
- Incyte Corporation
- Leica Corporation
- Millennium Pharmaceuticals
- Pharmacyclics
- Seattle Genetics Corporation
- Sysmex Corporation
- Ventana Medical Systems, Inc of the Roche Group
A revision of the nearly 8-year-old World Health Organization classification of the lymphoid neoplasms and the accompanying monograph is being published. It reflects a consensus among hematopathologists, geneticists, and clinicians regarding both updates to current entities as well as the addition of a limited number of new provisional entities. The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies. The major changes are reviewed with an emphasis on the most important advances in our understanding that impact our diagnostic approach, clinical expectations, and therapeutic strategies for the lymphoid neoplasms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据